Literature DB >> 24992041

Cyclin D2 plays a regulatory role in HBV replication.

Chun-li Song1, Ji-hua Ren1, Long-kuan Ran1, Yong-guo Li2, Xiao-song Li1, Xiang Chen1, Wan-yu Li1, Ai-long Huang1, Juan Chen3.   

Abstract

Hepatitis B virus (HBV) infection is the leading cause of liver diseases. However, the molecular mechanisms of HBV infection and carcinogenesis have not been fully elucidated. In this study, we found that cyclin D2 was upregualted in HBV-expressing cells and liver tissues of HBV-transgenic mice. Gene silencing of cyclin D2 inhibited HBV DNA replicative intermediates, 3.5 kb mRNA, core protein level, as well as the secretions of HBsAg and HBeAg. On the contrary, overexpression of cyclin D2 promoted HBV replication. Furthermore, cyclin D2 regulated HBV replication by enhancing the activity of HBV core and Sp1 promoters by targeting transcription factor CREB2. Silencing of CREB2 abolished enhancement of HBV replication induced by cyclin D2. Together, our study has uncovered a positive role of cyclin D2 in HBV replication. It is conceivable that therapeutic application of cyclin D2 inhibitor in HBV infection therapy.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cyclin D2; HBV promoter; HBV replication; Hepatitis B virus

Mesh:

Substances:

Year:  2014        PMID: 24992041     DOI: 10.1016/j.virol.2014.05.027

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  SIRT2 Promotes HBV Transcription and Replication by Targeting Transcription Factor p53 to Increase the Activities of HBV Enhancers and Promoters.

Authors:  Dai-Qing Wu; Qiu-Ying Ding; Na-Na Tao; Ming Tan; Yuan Zhang; Fan Li; Yu-Jiao Zhou; Mei-Ling Dong; Sheng-Tao Cheng; Fang Ren; Juan Chen; Ji-Hua Ren
Journal:  Front Microbiol       Date:  2022-05-19       Impact factor: 6.064

2.  Extremely Low-Frequency Electromagnetic Fields Affect the miRNA-Mediated Regulation of Signaling Pathways in the GC-2 Cell Line.

Authors:  Yong Liu; Wen-Bin Liu; Kai-Jun Liu; Lin Ao; Jia Cao; Julia Li Zhong; Jin-Yi Liu
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

3.  ZEB2 inhibits HBV transcription and replication by targeting its core promoter.

Authors:  Qiao He; Wanyu Li; Jihua Ren; Yecai Huang; Ying Huang; Qin Hu; Juan Chen; Weixian Chen
Journal:  Oncotarget       Date:  2016-03-29

4.  Transcriptome-Wide Analysis of Hepatitis B Virus-Mediated Changes to Normal Hepatocyte Gene Expression.

Authors:  Jason Lamontagne; Joshua C Mell; Michael J Bouchard
Journal:  PLoS Pathog       Date:  2016-02-18       Impact factor: 6.823

Review 5.  Mapping the Interactions of HBV cccDNA with Host Factors.

Authors:  Nur K Mohd-Ismail; Zijie Lim; Jayantha Gunaratne; Yee-Joo Tan
Journal:  Int J Mol Sci       Date:  2019-09-01       Impact factor: 5.923

6.  Development of a novel anti-hepatitis B virus agent via Sp1.

Authors:  Michiyo Hayakawa; Hideaki Umeyama; Mitsuo Iwadate; Y-H Taguchi; Yoshihiko Yano; Takashi Honda; Saori Itami-Matsumoto; Ritsuzo Kozuka; Masaru Enomoto; Akihiro Tamori; Norifumi Kawada; Yoshiki Murakami
Journal:  Sci Rep       Date:  2020-01-08       Impact factor: 4.379

7.  Global analysis of HBV-mediated host proteome and ubiquitylome change in HepG2.2.15 human hepatoblastoma cell line.

Authors:  Sen Yuan; Yousaf Tanzeel; Xuezhang Tian; Dandan Zheng; Naz Wajeeha; Jiaqi Xu; Yujia Ke; Zuopeng Zhang; Xiaojun Peng; Long Lu; Guihong Sun; Deyin Guo; Min Wang
Journal:  Cell Biosci       Date:  2021-04-17       Impact factor: 7.133

8.  Alteration of microRNA profiles by a novel inhibitor of human La protein in HBV-transformed human hepatoma cells.

Authors:  Jiaqian Pan; Shuangmei Tong; Jing Tang
Journal:  J Med Virol       Date:  2017-09-22       Impact factor: 2.327

9.  Transcriptome profiling of whitefly guts in response to Tomato yellow leaf curl virus infection.

Authors:  Liang Geng; Li-Xin Qian; Ruo-Xuan Shao; Yin-Quan Liu; Shu-Sheng Liu; Xiao-Wei Wang
Journal:  Virol J       Date:  2018-01-16       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.